We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Judge Enjoins FDA From Barring Truthful, Nonmisleading Off-Label Drug Promotion

Mealey's (August 19, 2015, 11:41 AM EDT) -- NEW YORK — A New York federal judge on Aug. 7 ruled that Amarin Pharma Inc. proposes to make “truthful and non-misleading” statements about its prescription fish oil drug and that such speech “may not form the basis of a prosecution for misbranding” by the Food and Drug Administration (Amarin Pharma, Inc., et al. v. United States Food and Drug Administration, et al., No. 15-3588, S.D. N.Y.; 2015 U.S. Dist. LEXIS 103944).

(Opinion available. Document #28-150820-010Z.)

Amarin Pharma Inc. makes a triglyceride-lowering drug called Vascepa, which...
To view the full article, register now.